KRKimberly P. Raghubar

Kimberly P. Raghubar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kimberly P. Raghubar has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Screening of Cognitive Symptoms During Treatment for Childhood Leukemia Predicts Post-Treatment Cognitive Functioning

    by Alyssa Krentzel, Joan Yu, Olga A. Taylor, Chi-Fan Lin, Emily Mason, Marilyn Hockenberry, Michael E. Scheurer, Austin L. Brown, Kimberly P. Raghubar

    Background: The current study describes the trajectory of caregiver-reported cognitive functioning for children treated for acute lymphoblastic leukemia (ALL) and correlations with post-treatment caregiver-reported and performance-based cognitive functioning. Method: The PROMIS parent proxy cognitive function questionnaire was collected at four time points during childhood ALL treatment for 40 participants who also completed post-treatment PROMIS parent proxy reports and neurocognitive evaluations. Results: Patients (52.5% male) were diagnosed with standard (45.0%) or high-risk B-ALL (47.5%) at a mean age of 7.80 years. During the first year of treatment, caregiver reports revealed a statistically significant ( p < .01) decline in child cognitive functioning of 0.37 SD (95% CI: [0.12–0.62]) evaluated using mixed-effects linear regression. Caregiver report of cognitive functioning at the end of the first year of treatment correlated with post-treatment ratings ( p < .05), after accounting for demographic and clinical factors. Post-treatment caregiver-reported cognitive functioning was significantly associated with estimated IQ ( p < .01), attention ( p < .05), word reading ( p < .05), and calculation ( p < .01). Discussion: Treatment for childhood ALL results in subtle changes in caregiver perception of cognitive functioning that are detectable shortly after diagnosis and may persist into survivorship. Furthermore, this study presents preliminary evidence for use of the PROMIS parent proxy cognitive function questionnaire as a screener for cognitive difficulties that may require further neurocognitive monitoring or comprehensive evaluation.

  • Open Access

    Clinical Correlates of Anxiety and Depression After Diagnosis of a Pediatric Brain Tumor

    by Bryony J. Lucas, Se‐Kang Kim, Joan Yu, Ana Sofia C. Ibarrola, Heather H. Stancel, Kavyaa Choudry, Mary Elizabeth Moody, Krystal K. Christopher, David R. Grosshans, Arnold C. Paulino, et al.

    Background: The prevalence and clinical correlates of symptoms of anxiety and depression in pediatric patients with brain tumors are not well described. We aimed to identify clinical characteristics that are correlated with elevated symptoms of anxiety and depression following initial diagnosis. Procedure: Pediatric patients diagnosed with a brain tumor at Texas Children's Hospital from 2012 to 2019 were enrolled. Using the parent‐proxy report form of the BASC‐2, patients were assessed for symptoms of anxiety and depression within 6 months of diagnosis. Correspondence analysis was applied to determine the correlation values ( r ) for anxiety and depression; r ≥ 0.71 was considered statistically significant as it explained at least 50% of the shared variance. Results: All patients ( n = 149, mean age = 9 years [range 3–18], 56% male) underwent a tumor‐directed surgery or biopsy. Overall, 24% ( n = 35) of patients had elevated symptoms of anxiety, and 15% ( n = 22) had elevated symptoms of depression. There was a strong correlation between elevated anxiety symptoms and surgical resection alone ( r = 0.96), surgery plus chemotherapy ( r = 0.86), and infratentorial tumors ( r = 1.00). Elevated depression symptoms correlated with a diagnosis of low‐grade glioma ( r = 1.00), infratentorial tumors ( r = 0.76), and low global intellectual functioning ( r = 0.81). Conclusions: Treatment type, tumor histology, tumor location, and global intellectual functioning are significantly associated with anxiety and depression symptoms in children with brain tumors close to the time of diagnosis. These findings may inform the provision of screening and supportive services to these high‐risk groups.

  • Episodes of acute methotrexate‐related neurotoxicity linked to compromised long‐term neurocognitive function

    by Rachel D. Harris, Olga A. Taylor, Kimberly P. Raghubar, Mariana Matheus Gonzalez, Mark Zobeck, M. Monica Gramatges, Karen R. Rabin, Michael E. Scheurer, Austin L. Brown

    Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but is associated with neurotoxicity. Information on long‐term outcomes following an acute neurotoxic event is limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients with (n = 25) and without (n = 146) a history of acute neurotoxicity. Compared to children with no documented on‐treatment neurotoxic event, children who experienced a neurotoxic event during treatment exhibited poorer performance on measures of fine motor function (p = .02) and attention (p = .02). Children with ALL who experience acute neurotoxicity may be candidates for early neuropsychological screening and intervention.


  • Adaptive, behavioral, and emotional outcomes following postoperative pediatric cerebellar mutism syndrome in survivors treated for medulloblastoma

    by Kimberly P. Raghubar, Andrew M. Heitzer, Fatema Malbari, Jason Gill, Roy V. Sillitoe, Livia Merrill, Johanna Escalante, M. Fatih Okcu, Guillermo Aldave, Avner Meoded, et al.

    OBJECTIVE: Patients who experience postoperative pediatric cerebellar mutism syndrome (CMS) during treatment for medulloblastoma have long-term deficits in neurocognitive functioning; however, the consequences on functional or adaptive outcomes are unknown. The purpose of the present study was to compare adaptive, behavioral, and emotional functioning between survivors with and those without a history of CMS. METHODS: The authors examined outcomes in 45 survivors (15 with CMS and 30 without CMS). Comprehensive neuropsychological evaluations, which included parent-report measures of adaptive, behavioral, and emotional functioning, were completed at a median of 2.90 years following craniospinal irradiation. RESULTS: Adaptive functioning was significantly worse in the CMS group for practical and general adaptive skills compared with the group without CMS. Rates of impairment in practical, conceptual, and general adaptive skills in the CMS group exceeded expected rates in the general population. Despite having lower overall intellectual functioning, working memory, and processing speed, IQ and related cognitive processes were uncorrelated with adaptive outcomes in the CMS group. No significant group differences or increased rates of impairment were observed for behavioral and emotional outcomes. CONCLUSIONS: Survivors with CMS, compared with those without CMS, are rated as having significant deficits in overall or general adaptive functioning, with specific weakness in practical skills several years posttreatment. Findings from this study demonstrate the high risk for ongoing functional deficits despite acute recovery from symptoms of CMS, highlighting the need for intervention to mitigate such risk.


  • Open Access

    Cognitive Sparing in Proton versus Photon Radiotherapy for Pediatric Brain Tumor Is Associated with White Matter Integrity: An Exploratory Study

    by Lisa E. Mash, Lisa S. Kahalley, Kimberly P. Raghubar, Naomi J. Goodrich-Hunsaker, Tracy J. Abildskov, Luz A. De Leon, Marianne MacLeod, Heather Stancel, Kelley Parsons, Brian Biekman, et al.

    Radiotherapy for pediatric brain tumors is associated with reduced white matter structural integrity and neurocognitive decline. Superior cognitive outcomes have been reported following proton radiotherapy (PRT) compared to photon radiotherapy (XRT), presumably due to improved sparing of normal brain tissue. This exploratory study examined the relationship between white matter change and late cognitive effects in pediatric brain tumor survivors treated with XRT versus PRT. Pediatric brain tumor survivors treated with XRT (n = 10) or PRT (n = 12) underwent neuropsychological testing and diffusion weighted imaging >7 years post-radiotherapy. A healthy comparison group (n = 23) was also recruited. Participants completed age-appropriate measures of intellectual functioning, visual-motor integration, and motor coordination. Tractography was conducted using automated fiber quantification (AFQ). Fractional anisotropy (FA), axial diffusivity (AD), and radial diffusivity (RD) were extracted from 12 tracts of interest. Overall, both white matter integrity (FA) and neuropsychological performance were lower in XRT patients while PRT patients were similar to healthy control participants with respect to both FA and cognitive functioning. These findings support improved long-term outcomes in PRT versus XRT. This exploratory study is the first to directly support for white matter integrity as a mechanism of cognitive sparing in PRT.


  • Superior verbal learning and memory in pediatric brain tumor survivors treated with proton versus photon radiotherapy.

    by Lisa E. Mash, Lisa S. Kahalley, M. Fatih Okcu, David R. Grosshans, Arnold C. Paulino, Heather Stancel, Luz De Leon, Elisabeth Wilde, Nilesh Desai, Zili D. Chu, et al.

    Radiotherapy for pediatric brain tumor has been associated with late cognitive effects. Compared to conventional photon radiotherapy (XRT), proton radiotherapy (PRT) delivers lower doses of radiation to healthy brain tissue. PRT has been associated with improved long-term cognitive outcomes compared to XRT. However, there is limited research comparing the effects of XRT and PRT on verbal memory. Survivors of pediatric brain tumor treated with either XRT (n = 29) or PRT (n = 51) completed neuropsychological testing > 1 year following radiotherapy. Performance on neuropsychological measures was compared between treatment groups using analysis of covariance. Chi-squared tests of independence were used to compare the frequency of encoding, retrieval, and intact memory profiles between treatment groups. Associations between memory performance and other neurobehavioral measures were examined using Pearson correlation. Overall, patients receiving PRT demonstrated superior verbal learning and recall compared to those treated with XRT. Encoding and retrieval deficits were more common in the XRT group than the PRT group, with encoding problems being most prevalent. The PRT group was more likely to engage in semantic clustering strategies, which predicted better encoding and retrieval. Encoding ability was associated with higher intellectual and adaptive functioning, and fewer parent-reported concerns about day-to-day attention and cognitive regulation. Results suggest that PRT is associated with verbal memory sparing, driven by effective encoding and use of learning strategies. Future work may help to clarify underlying neural mechanisms associated with verbal memory decline, which will better inform treatment approaches. (PsycInfo Database Record (c) 2023 APA, all rights reserved).


  • Longitudinal investigation of suicidal ideation and associated factors during pediatric acute lymphoblastic leukemia chemotherapy

    by Kimberly P. Raghubar, Tiffany Chambers, Ryan M. Hill, Olga Taylor, Marilyn Hockenberry, M. Casey Hooke, Pauline Mitby, Ida Ki Moore, Austin L. Brown, Michael E. Scheurer

    Objective: This study describes the prevalence of suicidal ideation (SI) during acute lymphoblastic leukemia (ALL) therapy and investigates the influence of clinical factors and physical symptoms on SI.Methods: The Children's Depressive Inventory (CDI‐2) was administered to ALL patients (diagnosed 2012–2017) at start of consolidation, delayed intensification (DI), maintenance cycle 1 (MC1), and maintenance cycle 2 (MC2) in a multi‐site study. SI was present if patients endorsed the item “I want to kill myself.” Logistic regression models evaluated associations between SI and sociodemographic factors; depressive symptoms; and below average, average, and above average symptom clusters identified using latent class analysis of pain, nausea, fatigue, and sleep.Results: Participants (n = 175) were 51% male, 75% high‐/very high‐risk disease, with a median age of 11.2 years at diagnosis (range: 7–18 years). Overall, 14.9% of patients (75% under age 12 years) endorsed SI during treatment, including 4% at start of consolidation, 9% at DI, 8% at MC1, and 4% at MC2. Non‐Hispanic Other patients were 10.9‐times (95% CI: 2.30–53.40) more likely than non‐Hispanic Whites to endorse SI (p = 0.003). The frequency of SI was higher in patients experiencing above average (53.3%) compared to below average (4.1%, p = 0.003) symptoms. Depressive symptoms were consistently associated with SI.Conclusions: SI during the initial year of childhood ALL was more prevalent in children under the age of 12 years, from ethnic groups not typically associated with increased risk, and who endorsed increased physical and depressive symptoms. Findings highlight the need for improved screening of mental health problems to mitigate symptoms of distress.


  • Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size

    by Mark D. McCurdy, Kimberly P. Raghubar, Krystal Christopher, M. Fatih Okcu, Elisabeth Wilde, Nilesh Desai, Zili D. Chu, Marsha Gragert, Heather Stancel, Emily H. Warren, et al.

    Background: The Neurological Predictor Scale (NPS) quantifies cumulative exposure to conventional treatment‐related neurological risks but does not capture potential risks posed by tumors themselves. This study evaluated the predictive validity of the NPS, and the incremental value of tumor location and size, for neurocognitive outcomes in early survivorship following contemporary therapies for pediatric brain tumors.Procedure: Survivors (N = 69) diagnosed from 2010 to 2016 were administered age‐appropriate versions of the Wechsler Intelligence Scales. Hierarchical multiple regressions examined the predictive and incremental validity of NPS score, tumor location, and tumor size.Results: Participants (51% female) aged 6‐20 years (M = 13.22, SD = 4.09) completed neurocognitive evaluations 5.16 years (SD = 1.29) postdiagnosis. The NPS significantly predicted Full‐Scale Intelligence Quotient (FSIQ; ΔR2 = .079), Verbal Comprehension Index (VCI; ΔR2 = 0.051), Perceptual Reasoning Index (PRI; ΔR2 = 0.065), and Processing Speed Index (PSI; ΔR2 = 0.049) performance after controlling for sex, age at diagnosis, and maternal education. Tumor size alone accounted for a significant amount of unique variance in FSIQ (ΔR2 = 0.065), PRI (ΔR2 = 0.076), and PSI (ΔR2 = 0.080), beyond that captured by the NPS and relevant covariates. Within the full model, the NPS remained a significant independent predictor of FSIQ (β = −0.249, P = 0.016), VCI (β = −0.223, P = 0.048), and PRI (β = −0.229, P = 0.037).Conclusions: Tumor size emerged as an independent predictor of neurocognitive functioning and added incrementally to the predictive utility of the NPS. Pretreatment disease burden may provide one of the earliest markers of neurocognitive risk following contemporary treatments. With perpetual treatment advances, measures quantifying treatment‐related risk may need to be updated and revalidated to maintain their clinical utility.


  • Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy

    by Emily A. H. Warren, Kimberly P. Raghubar, Paul T. Cirino, Amanda E. Child, Philip J. Lupo, David R. Grosshans, Arnold C. Paulino, M. Fatih Okcu, Charles G. Minard, M. Douglas Ris, et al.

    Background: Pediatric brain tumor survivors are at risk for poor social outcomes. It remains unknown whether cognitive sparing with proton radiotherapy (PRT) supports better social outcomes relative to photon radiotherapy (XRT). We hypothesized that survivors treated with PRT would outperform those treated with XRT on measures of cognitive and social outcomes. Further, we hypothesized that cognitive performance would predict survivor social outcomes.Procedure: Survivors who underwent PRT (n = 38) or XRT (n = 20) participated in a neurocognitive evaluation >1 year post radiotherapy. Group differences in cognitive and social functioning were assessed using analysis of covariance (ANCOVA). Regression analyses examined predictors of peer relations and social skills.Results: Age at evaluation, radiation dose, tumor diameter, and sex did not differ between groups (all p > .05). XRT participants were younger at diagnosis (XRT M = 5.0 years, PRT M = 7.6 years) and further out from radiotherapy (XRT M = 8.7 years, PRT M = 4.6 years). The XRT group performed worse than the PRT group on measures of processing speed (p = .01) and verbal memory (p < .01); however, social outcomes did not differ by radiation type. The proportion of survivors with impairment in peer relations and social skills exceeded expectation; χ2(1) = 38.67, p < .001; χ2(1) = 5.63, p < .05. Household poverty predicted peer relation difficulties (t = 2.18, p < .05), and verbal memory approached significance (t = −1.99, p = .05). Tumor diameter predicted social skills (t = −2.07, p < .05).Conclusions: Regardless of radiation modality, survivors are at risk for social challenges. Deficits in verbal memory may place survivors at particular risk. Results support monitoring of cognitive and social functioning throughout survivorship, as well as consideration of sociodemographic risk factors.


  • Association between fatigue and sleep disturbances during treatment for pediatric acute lymphoblastic leukemia and posttreatment neurocognitive performance

    by Priscilla Vasquez, Johanna Escalante, Kimberly P. Raghubar, Lisa S. Kahalley, Olga A. Taylor, Ida Ki Moore, Marilyn J. Hockenberry, Michael E. Scheurer, Austin L. Brown

    Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention.Methods: Pediatric patients (n = 120) with ALL (diagnosed 2011–2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models.Results: Participants (57.5% male and 79.1% Hispanic or non‐Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short‐term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention.Conclusions: Our findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long‐term neurocognitive performance. Sleep and fatigue may be targets for intervention to preserve cognitive functioning in survivors.